BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32272493)

  • 1. The Predictive Value of Early Changes in
    He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z
    Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.
    van Kruchten M; de Vries EG; Glaudemans AW; van Lanschot MC; van Faassen M; Kema IP; Brown M; Schröder CP; de Vries EF; Hospers GA
    Cancer Discov; 2015 Jan; 5(1):72-81. PubMed ID: 25380844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary study of
    Gong C; Yang Z; Sun Y; Zhang J; Zheng C; Wang L; Zhang Y; Xue J; Yao Z; Pan H; Wang B; Zhang Y
    Sci Rep; 2017 Jul; 7(1):6584. PubMed ID: 28747642
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Liu C; Ma G; Zhang J; Cheng J; Yang Z; Song S
    Ann Nucl Med; 2023 Dec; 37(12):675-684. PubMed ID: 37787851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
    Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
    Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with
    Gennari A; Brain E; De Censi A; Nanni O; Wuerstlein R; Frassoldati A; Cortes J; Rossi V; Palleschi M; Alberini JL; Matteucci F; Piccardo A; Sacchetti G; Ilhan H; D'Avanzo F; Ruffilli B; Nardin S; Monti M; Puntoni M; Fontana V; Boni L; Harbeck N;
    Ann Oncol; 2024 Jun; 35(6):549-558. PubMed ID: 38423389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of tumour heterogeneity by
    Liu C; Hu S; Xu X; Zhang Y; Wang B; Song S; Yang Z
    Breast Cancer Res; 2022 Aug; 24(1):57. PubMed ID: 36028895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
    Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP
    J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
    Kurland BF; Peterson LM; Lee JH; Schubert EK; Currin ER; Link JM; Krohn KA; Mankoff DA; Linden HM
    Clin Cancer Res; 2017 Jan; 23(2):407-415. PubMed ID: 27342400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head-to-Head Evaluation of
    Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
    J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
    Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
    Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Feasibility Study of
    Chae SY; Kim SB; Ahn SH; Kim HO; Yoon DH; Ahn JH; Jung KH; Han S; Oh SJ; Lee SJ; Kim HJ; Son BH; Gong G; Lee HS; Moon DH
    J Nucl Med; 2017 Apr; 58(4):563-568. PubMed ID: 27688475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can
    Gupta M; Datta A; Choudhury PS; Dsouza M; Batra U; Mishra A
    World J Nucl Med; 2017; 16(2):133-139. PubMed ID: 28553180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
    Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
    J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Wang Y; Ayres KL; Goldman DA; Dickler MN; Bardia A; Mayer IA; Winer E; Fredrickson J; Arteaga CL; Baselga J; Manning HC; Mahmood U; Ulaner GA
    Clin Cancer Res; 2017 Jun; 23(12):3053-3060. PubMed ID: 28011460
    [No Abstract]   [Full Text] [Related]  

  • 16. Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy.
    van Kruchten M; Glaudemans AWJM; de Vries EFJ; Schröder CP; de Vries EGE; Hospers GAP
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1674-1681. PubMed ID: 26091705
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
    Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Nienhuis HH; van Kruchten M; Elias SG; Glaudemans AWJM; de Vries EFJ; Bongaerts AHH; Schröder CP; de Vries EGE; Hospers GAP
    J Nucl Med; 2018 Aug; 59(8):1212-1218. PubMed ID: 29602822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtype-Guided
    Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
    Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual time point
    Yamagishi Y; Koiwai T; Yamasaki T; Einama T; Fukumura M; Hiratsuka M; Kono T; Hayashi K; Ishida J; Ueno H; Tsuda H
    BMC Cancer; 2019 Nov; 19(1):1146. PubMed ID: 31775675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.